Matthew Kulke

Last updated
Matthew Helmut Kulke
Alma mater Princeton University
UCSF School of Medicine
Harvard Medical School
Occupation(s)Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Boston University School of Medicine.
Years active1992-Present [1]

Matthew Kulke is an American cancer researcher. He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine. [2] [3] His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition. [4] [5] His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor, [6] for the treatment of patients with carcinoid syndrome. [7] He has also contributed to early and late stage clinical trials of temozolomide, sunitinib, [8] everolimus, and peptide receptor radiotherapy for neuroendocrine tumors. [9] [10]

Contents

Education

Kulke received his undergraduate degree from Princeton University, his M.D. from the University of California, San Francisco School of Medicine, completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in Medical Oncology at Dana-Farber Cancer Institute. [10] He holds a master's degree in medical science from Harvard Medical School. [10]

Career

After his education, Kulke subsequently joined the faculty at Dana-Farber Cancer Institute and Harvard Medical School [11] where he rose to the rank of Professor of Medicine and was the founding director of the neuroendocrine tumor program. [5] He has served in his current role at Boston University since 2018. His accomplishments in the field have been recognized at the national and international level. He has served as chair of the National Cancer Institute's Neuroendocrine Tumor Task Force from 2011-2014, [12] as chair of the North American Neuroendocrine Tumor Society from 2014-2016, and as chair the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee from 2010-2017. [5]

Related Research Articles

<span class="mw-page-title-main">Carcinoid</span> A slow-growing type of neuroendocrine tumor

A carcinoid is a slow-growing type of neuroendocrine tumor originating in the cells of the neuroendocrine system. In some cases, metastasis may occur. Carcinoid tumors of the midgut are associated with carcinoid syndrome.

Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary to neuroendocrine tumors. The syndrome is caused by neuroendocrine tumors most often found in the gut releasing biologically active substances into the blood causing symptoms such as flushing and diarrhea, and less frequently, heart failure, vomiting and bronchoconstriction.

<span class="mw-page-title-main">Sunitinib</span> Cancer medication

Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.

<span class="mw-page-title-main">Neuroendocrine tumor</span> Medical condition

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung, and the rest of the body.

<span class="mw-page-title-main">Appendix cancer</span> Medical condition

Appendix cancer are very rare cancers of the vermiform appendix.

<span class="mw-page-title-main">Octreotide scan</span>

An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111, and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin. A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body, typically by a SPECT technique. A technetium-99m based radiopharmaceutical kit is also available.

<span class="mw-page-title-main">DOTA-TATE</span> Eight amino-acid long peptide covalently bonded to a DOTA chelator

DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.

<span class="mw-page-title-main">Edotreotide</span> Chemical compound

Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. When used therapeutically it is an example of peptide receptor radionuclide therapy.

Advanced Accelerator Applications is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.

<span class="mw-page-title-main">Pancreatic neuroendocrine tumor</span> Medical condition

Pancreatic neuroendocrine tumours, often referred to as "islet cell tumours", or "pancreatic endocrine tumours" are neuroendocrine neoplasms that arise from cells of the endocrine (hormonal) and nervous system within the pancreas.

Hepatic artery embolization, also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. The embolization therapy can reduce the size of the tumor, and decrease the tumor's impact such its hormone production, effectively decreasing symptoms. The treatment was initially developed in the early 1970s. The several types of hepatic artery treatments are based on the observation that tumor cells get nearly all their nutrients from the hepatic artery, while the normal cells of the liver get about 70-80 percent of their nutrients and 50% their oxygen supply from the portal vein, and thus can survive with the hepatic artery effectively blocked. In practice, hepatic artery embolization occludes the blood flow to the tumors, achieving significant tumor shrinkage in over 80% of people. Shrinkage rates vary.

<span class="mw-page-title-main">Telotristat ethyl</span> Chemical compound

Telotristat ethyl is a prodrug of telotristat, which is an inhibitor of tryptophan hydroxylase. It is formulated as telotristat etiprate — a hippurate salt of telotristat ethyl.

Sandip Basu is an Indian physician of Nuclear Medicine and the Head, Nuclear Medicine Academic Program at the Radiation Medicine Centre. He is also the Dean-Academic (Health-Sciences), BARC at Homi Bhabha National Institute and is known for his services and research in Nuclear Medicine, particularly on Positron emission tomography diagnostics and Targeted Radionuclide Therapy in Cancer. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Nuclear Medicine in 2012.

<span class="mw-page-title-main">Andreas Kjær (scientist)</span> Danish physician-scientist

Andreas Kjær is a Danish physician-scientist and European Research Council (ERC) advanced grantee. He is professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. He is board certified in Nuclear Medicine and his research is focused on molecular imaging with PET and PET/MRI and targeted radionuclide therapies (theranostics) in cancer. His achievements include development of several new PET tracers that have reached first-in-human clinical use. He has published more than 400 peer-review articles, filed 10 patents, supervised more than 40 PhD students and received numerous prestigious scientific awards over the years. He is a member of the Danish Academy of Technical Sciences

A small intestine neuroendocrine tumor is a carcinoid in the distal small intestine or the proximal large intestine. It is a relatively rare cancer and is diagnosed in approximately 1/100000 people every year. In recent decades the incidence has increased. The prognosis is comparatively good with a median survival of more than 8 years. The disease was named by Siegfried Oberndorfer, a German pathologist, in 1907.

<span class="mw-page-title-main">Peptide receptor radionuclide therapy</span> Type of radiotherapy

Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).

Lutetium (<sup>177</sup>Lu) chloride Radioactive compound used for radiopharmaceutical labeling

Lutetium (177Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy. It is an isotopomer of lutetium(III) chloride containing the radioactive isotope 177Lu, which undergoes beta decay with a half-life of 6.65 days.

Lutetium (<sup>177</sup>Lu) oxodotreotide Chelate of Lu-177 with DOTA-TATE, a peptide derivative bound to a DOTA molecule

Lutetium (177Lu) oxodotreotide (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.

<span class="mw-page-title-main">Pamela Kunz</span> American oncologist

Pamela Lyn Kunz is an American oncologist. She is the leader of the Gastrointestinal Cancers Program at Yale Cancer Center and Smilow Cancer Hospital and director of GI Medical Oncology within the Section of Medical Oncology. She was formerly the director of the Stanford Neuroendocrine Tumor Program before leaving, in part due to gender harassment.

<span class="mw-page-title-main">Toni Choueiri</span> American medical oncologist

Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs and prognostic factors in advanced renal cell carcinoma (RCC). Choueiri also co-established the International metastatic database Consortium with Daniel Heng. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

References

  1. ↑ "Dr. Matthew Kulke, MD". Health Grades. Retrieved 2020-11-19.
  2. ↑ "Matthew Helmut Kulke, MD". Boston University. Retrieved 2020-11-13.
  3. ↑ "Matthew Kulke, MD, Joins BUMC". Boston University School of Medicine. 2017-11-21. Retrieved 2020-11-20.
  4. ↑ Strosberg, Jonathan; El-Haddad, Ghassan; Wolin, Edward; Hendifar, Andrew; Yao, James; Chasen, Beth; Mittra, Erik; Kunz, Pamela L.; Kulke, Matthew H.; Jacene, Heather; Bushnell, David; o'Dorisio, Thomas M.; Baum, Richard P.; Kulkarni, Harshad R.; Caplin, Martyn; Lebtahi, Rachida; Hobday, Timothy; Delpassand, Ebrahim; Van Cutsem, Eric; Benson, Al; Srirajaskanthan, Rajaventhan; Pavel, Marianne; Mora, Jaime; Berlin, Jordan; Grande, Enrique; Reed, Nicholas; Seregni, Ettore; Öberg, Kjell; Lopera Sierra, Maribel; et al. (2019-01-12). "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors". New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. PMC   5895095 . PMID   28076709.
  5. 1 2 3 "MATTHEW H. KULKE, MD". NANETS. Retrieved 2020-11-19.
  6. ↑ Pavel, Marianne; Gross, David J.; Benavent, Marta; Perros, Petros; Srirajaskanthan, Raj; Warner, Richard R P.; Kulke, Matthew H.; Anthony, Lowell B.; Kunz, Pamela L.; Hörsch, Dieter; Weickert, Martin O.; Lapuerta, Pablo; Jiang, Wenjun; Kassler-Taub, Kenneth; Wason, Suman; Fleming, Rosanna; Fleming, Douglas; Garcia-Carbonero, Rocio (2018). "Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial". Endocrine-Related Cancer. 25 (3): 309–322. doi:10.1530/ERC-17-0455. PMC   5811631 . PMID   29330194 . Retrieved 2020-11-20.
  7. ↑ Kulke, Matthew H.; Hörsch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Öberg, Kjell; Welin, Staffan; Warner, Richard R.P.; Lombard-Bohas, Catherine; Kunz, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; Pavel, Marianne (2017-01-01). "Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome". Journal of Clinical Oncology. 35 (1): 14–23. doi:10.1200/JCO.2016.69.2780. PMID   27918724 . Retrieved 2020-11-20.
  8. ↑ Kulke, Matthew H.; Lenz, Heinz-Josef; Meropol, Neal J.; Posey, James; Ryan, David P.; Picus, Joel; Bergsland, Emily; Stuart, Keith; Tye, Lesley; Huang, Xin; Li, Jim Z.; Baum, Charles M.; Fuchs, Charles S. (2008). "Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors". Journal of Clinical Oncology. 26 (20): 3403–3410. doi: 10.1200/JCO.2007.15.9020 . PMID   18612155.
  9. ↑ Abbott, Amanda; Sakellis, Christopher G.; Andersen, Eric; Kuzuhara, Yuji; Gilbert, Lauren; Boyle, Kelly; Kulke, Matthew H.; Chan, Jennifer A.; Jacene, Heather A.; Van Den Abbeele, Annick D. (2018-08-03). "Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division". Journal of Nuclear Medicine Technology. 46 (3): 237–244. doi: 10.2967/jnmt.118.209148 . PMID   30076245. S2CID   51909664 . Retrieved 2020-11-20.
  10. 1 2 3 "Matthew H Kulke, MD". Boston Medical University. Retrieved 2020-11-13.
  11. ↑ "MATTHEW H. KULKE, MD". Dana Farber/Harvard Cancer Center. Retrieved 2020-11-14.
  12. ↑ "Executive Summary of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting" (PDF). Cancer.gov. Retrieved 2020-11-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.